Materias dentro de su búsqueda.
Mostrando 5,561 - 5,580 Resultados de 5,950 Para Buscar 'Hanussen~', tiempo de consulta: 4.31s Limitar resultados
  1. 5561
    “…CITATION: Clemente DB, Casas M, Vilahur N, Begiristain H, Bustamante M, Carsin AE, Fernández MF, Fierens F, Gyselaers W, Iñiguez C, Janssen BG, Lefebvre W, Llop S, Olea N, Pedersen M, Pieters N, Santa Marina L, Souto A, Tardón A, Vanpoucke C, Vrijheid M, Sunyer J, Nawrot TS. 2016. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prenatal Ambient Air Pollution, Placental Mitochondrial DNA Content, and Birth Weight in the INMA (Spain) and ENVIRONAGE (Belgium) Birth Cohorts
  2. 5562
    “…CITATION: Pieters N, Janssen BG, Dewitte H, Cox B, Cuypers A, Lefebvre W, Smeets K, Vanpoucke C, Plusquin M, Nawrot TS. 2016. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Biomolecular Markers within the Core Axis of Aging and Particulate Air Pollution Exposure in the Elderly: A Cross-Sectional Study
  3. 5563
    “…DECLARATION OF INTEREST: D.A. has served on scientific advisory boards for Novartis, Eli Lilly, Janssen, Prana and Pfizer, and as Editor-in-Chief for International Psychogeriatrics; received speaker honoraria from Pfizer and Lundbeck, and research support from Eli Lilly, GlaxoSmithKline, Forest Laboratories, Novartis, and CSIRO. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Alterations in dorsal and ventral posterior cingulate connectivity in APOE ε4 carriers at risk of Alzheimer's disease
  4. 5564
    “…Additional research is needed to confirm our findings in other populations and to evaluate potential consequences later in life. CITATION: Janssen BG, Saenen ND, Roels HA, Madhloum N, Gyselaers W, Lefebvre W, Penders J, Vanpoucke C, Vrijens K, Nawrot TS. 2017. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Fetal Thyroid Function, Birth Weight, and in Utero Exposure to Fine Particle Air Pollution: A Birth Cohort Study
  5. 5565
    “…There is also an indication of improvement in OS, albeit with a higher uncertainty due to the low number of events. FUNDING: Janssen-Cilag Ltd. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-017-0564-1) contains supplementary material, which is available to authorized users.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
  6. 5566
    “…CONCLUSION: This study shows that greater and more prolonged exposure to hyperglycemia increases the risk of micro- and macrovascular complications. FUNDING: Janssen Pharmaceutica NV. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-017-0301-4) contains supplementary material, which is available to authorized users.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study
  7. 5567
    “…Faragon, Abbvie, BMS, Gilead, Janssen, Merck: Speaker’s Bureau, Speaker honorarium; P. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic
  8. 5568
    “…Huhn, Gilead: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient; ViiV Healthcare: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient; Janssen: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient; Theratechnologies: Scientific Advisor, Consulting fee; Proteus: Grant Investigator, Grant recipient.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2235. A Collaborative Drug Therapy Management Model for the Treatment of Hepatitis C Virus (HCV) in an Urban Clinic
  9. 5569
    por Maki, Gina, Chaudhry, Zohra, Brar, Indira
    Publicado 2018
    “…Brar, Gilead: Research Contractor and Speaker’s Bureau, Research grant and Speaker honorarium. Janssen: Research Contractor and Speaker’s Bureau, Research grant and Speaker honorarium. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    557. Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV-Infected Patients
  10. 5570
    “…Allecra Therapeutics, Amplyx, Actelion, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, IQVIA, Janssen, Matinas, Menarini, Merck/MSD, Paratek, PSI, Scynexis, Seres, Summit, Tetraphase, Vical: Consultant, Consulting fee. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    372. Attributable Mortality of Candidemia After Introduction of Echinocandins
  11. 5571
    “…Huhn, Gilead: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient; ViiV Healthcare: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient; Janssen: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient; Theratechnologies: Scientific Advisor, Consulting fee; Proteus: Grant Investigator, Grant recipient.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2208. Fibrosis Surveillance by Transient Elastography in Patients with Untreated Hepatitis C Infection
  12. 5572
    “…Jain, Gilead Sciences: Grant Investigator, Grant recipient and Research support. Janssen: Investigator, Research support. GSK/ViiV: Investigator, Consulting fee and Research support. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2207. Barriers to HCV Treatment in a Safety-Net Hospital System
  13. 5573
    por Hyer, Randall N, Janssen, Robert
    Publicado 2018
    “…Hyer, Dynavax Technologies Corporation: Employee and Shareholder, Salary and Stock options. R. Janssen, Dynavax Technologies Corporation: Employee and Shareholder, Salary and Stock options.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2287. Recently Approved HEPLISAV-B(R) [Hepatitis B Vaccine (Recombinant), Adjuvanted] Shows a Higher Proportion of Subjects Achieving Seroprotection With a More Consistent Immune Response Compared With Engerix-B(R) [Hepatitis B Vaccine (Recombinant)] in Three Comparative Trials
  14. 5574
    “…GlaxoSmithKline: Investigator, Salary. Alios Biopharma/Janssen: Investigator, Salary. Pfizer: Consultant, Consulting fee and Speaker honorarium. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2469. Knowledge, Attitudes, Confidence, and Hesitancy Toward Vaccines Among Residents in Pediatric and Family Practice Programs
  15. 5575
    por Verna, John, Austin, Stephen
    Publicado 2018
    “…DISCLOSURES: J. Verna, Janssen Pharmaceuticals, Inc.: Investigator, Research support.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
  16. 5576
    “…My JAKE, a mobile and Web-based mobile health (mHealth) app that is part of the Janssen Autism Knowledge Engine—a dynamically updated clinical research system—was designed to help caregivers of individuals with ASD to continuously log symptoms, record treatments, and track progress, to mitigate difficulties associated with retrospective reporting. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Caregiver Daily Reporting of Symptoms in Autism Spectrum Disorder: Observational Study Using Web and Mobile Apps
  17. 5577
    “…[Image: see text] DISCLOSURES: Scott Halperin, MD, GlaxoSmithKline: Ad hoc advisory boards, Other Financial or Material Support, Research Grant; Janssen Pharm: Research Grant; sanofi pasteur: Ad hoc advisory boards, Other Financial or Material Support, Research Grant.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2744. A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (Laboratory Code, FB-631) Co-administered with Seasonal TIV (2013–2014) to Healthy Adults ≥18–50 Years of Age
  18. 5578
    “…Wild animals were immobilized using a combination of etorphine hydrochloride (M99® Krüger-Med South Africa) at 0.5–2 mg/kg and azaperone (Stresnil®, Janssen Pharmaceuticals (Pty.) Ltd., South Africa) at 0.1 mg/kg using a Dan-Inject® rifle (Dan-Inject APS, Sellerup Skovvej, Denmark) fitted with a 3 ml dart syringe and for reversal, naltrexone (Trexonil® Kruger-Med South Africa) at 1.5 mg IM was used, and cattle were restrained by the owners for blood collection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Seroprevalence of Foot and Mouth Disease Virus Infection in Some Wildlife and Cattle in Bauchi State, Nigeria
  19. 5579
    “…DISCLOSURES: Octavio Ramilo, MD, Bill & Melinda Gates Foundation (Grant/Research Support)Janssen (Grant/Research Support, Advisor or Review Panel member)Medimmune (Grant/Research Support)Merck (Advisor or Review Panel member)NIH/NIAID (Grant/Research Support)Pfizer (Consultant, Advisor or Review Panel member)Sanofi/Medimmune (Consultant, Advisor or Review Panel member)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1331. Reducing Inpatient Antimicrobial Treatment Duration for Febrile Infants through Implementation of Rapid Diagnostic Testing and Clinical Risk Definition
  20. 5580
    “…Koren, PharmD, BCPS, AAHIVP, Gilead Sciences (Advisor or Review Panel member)Janssen Pharmaceuticals (Advisor or Review Panel member)Thera Technologies (Advisor or Review Panel member)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1040. Real-World Implementation of Dolutegravir-Lamivudine to Achieve and Maintain HIV-1 Viral Suppression at an Academic Medical Center
Herramientas de búsqueda: RSS